News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1

Study Status:

Active

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The goal of this study is to evaluate, over a 12-week induction period, the safety and efficacy of mirikizumab in patients with moderately to severely active UC who have an inadequate response to, loss of response to, or are intolerant to corticosteroid or immunomodulator therapy for UC (termed “conventionalfailed”), and those who have an inadequate response to, loss of response to, or are intolerant to biologic therapy for UC (termed “biologic-failed”).

Information: 

Principal Investigator
Sriramachandra Badiga, MD
Type of Trial
Prospective/Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram